brodalumab
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Brodalumab, an interleukin‐17 receptor A inhibitor, demonstrated rapid and robust efficacy with a favorable safety profile in…
Dear Editor, Acrodermatitis continua of Hallopeau (ACH) is a rare, chronic pustolosis involving one or more fingers or toes; the…
Brodalumab, a fully human antibody of the interleukin-17 receptor, is highly effective in the treatment of moderate-to-severe…
Objective. To evaluate the effect of brodalumab on psoriasis signs and symptoms assessed by the Psoriasis Symptom Inventory (PSI…
BACKGROUND
Monoclonal antibodies that target both Interleukin (IL)-12 and IL-23 have shown great efficacy in the treatment of…
UNLABELLED
Abstract Background: Studies investigating the molecular basis of psoriasis have established the central roles of TNF…
Background New agents with novel mechanisms of action are needed to treat the growing pool of patients with psoriatic arthritis…
Background A potential role of IL-17 in the pathogenesis and ongoing inflammation of psoriatic disease, with similar pathways…
On April 2, Amgen in Thousand Oaks, California, and AstraZeneca in London, announced a partnership to develop five monoclonal…